Clinical Trials Logo

Clinical Trial Summary

The performance of prostatic biopsies is an essential element to confirm the diagnosis of prostate cancer and to specify the characteristics of the tumor in terms of stage and grade. The first route of prostatic biopsies is mainly transrectal with passage of a needle introduced into the guide fixed on the endorectal ultrasound probe. There is another possible access route, transperineal, with prostatic puncture by a needle introduced transcutaneously, guided by an endorectal ultrasound image. The first transperineal route would offer the first benefit for the patient, to reduce the infectious risk inherent in the endorectal way. It would also reduce the risk of rectal bleeding. In addition, the transperineal pathway appears to be able to improve the detection threshold of prostatic tumours located on the anterior part of the gland due to the angle of penetration of the needle and its more anterior positioning relative to the prostate. There is currently no randomized comparison study of the transperineal versus transrectal procedure on infectious risk. The aim of the project is to enable this comparative study, within our institution where experienced urologist surgeons practice.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05763355
Study type Interventional
Source Elsan
Contact Pierre-Thierry PIECHAUD, MD
Phone (0)6.09.71.58.67
Email pthpiechaud@hotmail.fr
Status Recruiting
Phase N/A
Start date December 15, 2023
Completion date December 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01819740 - Analysis of a New Biomarker for Prostate Cancer Diagnosis N/A